Next Phase Newsletter

A venture capital firm that is based in Western USA with its parent company based in China, currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. With their first fund, the firm preferred to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

Now, the firm is currently raising a second fund with a target size of $200M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. The e firm is in the process of launching an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources, especially for global market entry and tapping into their network of China-based investors and partners. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, digital health, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm based in the USA is focused on early and growth-stage biotech and medical device companies. The group’s initial investments typically are in the $3M-$5M range and are usually in the form of straight equity, but may use convertible notes in select situations. The firm look to take meaningful stake in portfolio companies and play an active role in their development. The firm is open to companies based in the U.S., with a specific interest in companies located outside of the major biotech hubs, such as Boston or San Francisco.

The firm is most interested in the biotech/therapeutics space and will consider medtech companies on a secondary basis. The firm does not invest in diagnostic or digital health companies. The firm is mostly opportunistic in terms of technology type and indication area, however the group prioritizes companies with products addressing unmet medical need and unique mechanisms of action. For early-stage companies, the firm targets companies who have at least had a pre-IND meeting with the FDA and invest in companies ranging from pre-clinical to Ph. II clinical trials.

The firm has no strict company or management team requirements, but does look to be a very active investor and always requires a board seat along with an investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A family office investment vehicle representing the interests of USA East Coast based family offices, is looking to invest in ground-breaking life science and medical device technologies. While the firm is very flexible in terms of investment size, they are generally looking to invest a minimum of $0.5 million per round. The firm is open to Investing in companies located throughout North America and Europe.

The firm is looking for breakthrough technologies with a strong social ethos in the Therapeutics, Medical Devices, and Diagnostics Sectors that address underserved medical needs or provide innovative and disruptive approaches to common medical procedures and treatments. The firm invests on an opportunistic basis and is especially interested in areas of intersecting technologies, such as nucleic acid-based drugs and delivery, regenerative medicine and cell-based therapeutics. The firm is less interested in small molecules and generally will not consider biosimilars or other technologies for which there is already multiple therapeutic options. The firm is looking for niche disease areas where disruptive therapeutics have the potential to be truly disease-modifying, not just provide symptomatic relief or palliative care. The firm typically is interested in preclinical stage assets that have well-developed animal model dossiers to Phase II or early Phase III stage assets. The firm’s investment mandate particularly focuses on “smart” clinical trial formats such as adaptive trials and Master Protocol trials for capital efficiency. For devices, the firm is looking for devices that address and perhaps substitute for a pharmacologic in a given therapeutic market, such as deep brain stimulation technologies and orthopedics. The firm is generally not interested in cardiovascular disease or diabetes.

The firm is currently reviewing co-investment opportunities in private companies and on an opportunistic basis, considering investment in micro-and small-cap public companies as a direct investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A Korea-based investment firm manages several funds that focus primarily on the small- and mid-cap market in Korea, with around $500M AUM. Recently, the firm has closed a biotech-focused fund that will invest in global start-ups. The firm’s size of investment will depend on the stage of the company and will actively engage in follow-on investments as well. The firm actively seeks global opportunities.

The firm invests broadly across therapeutics, medical devices, and diagnostics, with the strongest interest in therapeutics. The firm is open to all types of modalities and is most interested in oncology and immunology indications as well as liver diseases such as NASH.

The firm seeks management teams with strong scientific expertise and experienced management teams. The firm may act as either a lead or co-investor and will not require a board seat post-investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital/private equity firm based in Shanghai, China. The firm manages both US and RMB denominated funds. The firm invests in Series A rounds at $1-2M, though its sweet spot is investing $10-15M in Series B/C rounds. The firm works closely with local provincial Chinese governments, allowing them the ability to bring technology successfully into the Chinese market. The firm will generally not invest in the seed stage, and seeks opportunities globally.

The firm invests in pharmaceuticals and Class II (510k) medical devices, including an interest in 505(b)(2) repurposed compounds, as well as healthcare-related industries. The firm is interested in all therapeutic areas and in early to mid development stage companies. The firm focuses on unmet medical needs with a China market potential.

The firm does not have management team requirements. The firm will typically take a board seat post-investment, and has the capability to lead and co-invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A venture capital firm with offices in USA and Canada is considering opportunities for investment out its third, most recent fund. The firm leads or co-leads seed investments, typically in the $500K-$1.5M range, in seed – small A rounds, and will provide additional capital to portfolio companies of up to $8M from the primary fund and up to an additional $8M from the LP co-investment fund, over the life of the investment. The firm looks to make 3-5 investments per year.

The firm has invested in a variety of med-tech companies including a company with a drug delivery platform technology and a range of digital health companies. Moving forward the firm will be more focused on diagnostics, drug delivery and platform technologies capable of generating re-purposed drugs – emphasis placed on short sales cycles and de-risked assets. The firm is agnostic in regards to therapeutic type and will consider large and small molecules as well as re-purposed or biosimilar assets and platform technologies. The firm prefers to invest early in a therapeutic’s life cycle, typically in preclinical or phase I, and is opportunistic in terms of indication.

The firm only considers companies with experienced management teams, and requires a board seat with every investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

A global venture capital firm based in Menlo Park, California is investing from a fund of over $600 million. The firm focuses on making equity investments into the life science and technology spaces from seed to late venture stage. The investment size is varied, and typically it ranges from $1 million to $20 million. The firm will invest in companies based in the US, India and Israel.

The firm is currently looking for new opportunities in the Biotech Therapeutics, Medical Devices and Healthcare IT sectors. The firm will also consider Diagnostics, but that will not be its focus. For Therapeutics and Medical Devices, the firm is extremely opportunistic in terms of subsectors and indications. The firm is interested in companies targeting orphan diseases. The firm is generally looking for companies in the clinical stage of development, but it also considers preclinical companies one or two years from clinics, as well as companies near commercial stages dependent on the case.

The firm primarily invests in private companies, and considers pre-revenue companies. The firm doesn’t have specific requirements for company’s management team or revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.